In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

Read by Ruxandra Christodorescu



Main conclusions

Empagliflozin decreased cardiovascular death or heart failure hospitalisation risk across the range of baseline health status. Empagliflozin improved health status across various domains, and this benefit was sustained during long-term follow-up.

Type of Study

Complementary analysis - aimed to evaluate whether the benefits of empagliflozin varied by baseline health status assessed by the Kansas City Cardiomyopathy Questionnaires-clinical summary score and how empagliflozin impacted patient-reported outcomes - of the EMPEROR-Reduced trial, a randomised, double-blind, placebo-controlled, trial that enrolled 3730 patients whith chronic HF and a left ventricular ejection fraction ≤40%.

Importance for clinical practice

Patiens with HEFrEF should be treated with medications for improving outcome but also for improving the quality of life : empagliflozin showed benefits in both endpoints.

References

Javed Butler, Stefan D Anker, Gerasimos Filippatos, Muhammad Shahzeb Khan, João Pedro Ferreira, Stuart J Pocock, Nadia Giannetti, James L Januzzi, Ileana L Piña, Carolyn S P Lam et al. 

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

European Heart Journal, 2021,(42) 13; 1203-1212